Canada’s vaccine strategy; a lesson in poor risk management
Henry Ford once said quality is doing it right when no one is looking. The same can be said about risk management. It’s easy to do the right thing when calamity impacts your business, and all eyes are suddenly upon you, preaching the imperativeness of risk management and resilience. But when the headlines move on to the next big story and the impacts of the last disaster have finished settling upon your balance sheet, it’s easy to forget the value of risk mitigation tactics and opt to save the money instead.Lest we forget, it’s why systematic and quantified risk management processes are imperative.Canada’s vaccine rollout is a disgrace, and it’s putting lives and the economy at risk. And quite frankly, I’m outraged, as we all should be, as it seems, perhaps Canada simply forgot. Or worse, it chose to save the dollars instead.As Trudeau himself pointed out, decades ago, Canada had vaccine production capacity, but this no longer remains the case, leaving the country reliant on importing vaccines from Europe. We all know well the threats that lay in global supply chains, not the least of which stem from geopolitics. And as governments tend to think about their own populations first, vaccine protectionism is on the rise, making the reliance on agreements signed across an ocean a high-risk move that has left people’s lives hanging in the balance.
Hedging Bets; Trudeau's last-minute risk mitigation efforts
As of Feb. 20, only 3.72 per cent of Canadians have received at least one shot. Comparatively, Israel, the world leader, sits at 82.4 per cent, the United Kingdom at 26.3 per cent, and the U.S. at 18 per cent.In Canada, health care systems, including the managing and performing of vaccinations, are run by the individual provinces. However, the federal government is responsible for regulating drugs and vaccines and negotiating pricing and contracts. This means that Mr Trudeau inherited the responsibility for procuring the countries vaccine requirements along with the pandemic.Hedging his bets, Trudeau placed orders with seven manufacturers for a total of $4.6 billion worth of vaccines, or up to . Although the number of vaccines on order perhaps makes for good optics and was an effort to mitigate risks, only two of the seven vaccines are currently approved. Dr Scott, a professor of medicine at Dalhousie University in Halifax and the medical director of the Canadian Center for Vaccinology, points out, “There’s never been a vaccine rollout where there weren’t shortages because of issues around working the bugs out of the manufacturing. So anybody who didn’t anticipate that there’d be some hiccups in the manufacturing process just wasn’t aware of the past.”And, as was to be expected, shipments from Europe have been delayed. Last week Canada received about 70,000 doses from Pfizer, and another 168,000 are expected to deliver this upcoming week, both being smaller sized shipments than was initially planned.And so, under pressure to pick up the pace on the vaccine rollout, the federal government withdrew 1.9 million doses from COVAX, an international fund fighting for equitable global distribution. The move drew sharp criticism from international organisations and opposition leaders.Trudeau has defended his actions by highlighting that Canada is one of the top contributors to the program, and countries that contribute to the program are allowed to withdraw. The Federal Government has since pledged another $75 million to the fund, bringing Canada’s total contribution to $940 million (in comparison, Britain has pledged $971 million.) However, it remains the only country in the G7 to “double-dip” by withdrawing from the same program it supports.The lack of any significant vaccine production capabilities in the country has left us at an extreme disadvantage when facing a global pandemic. So how did we end up playing a game of high stakes with Canadian lives, and what are we doing about it?Head over to Mitigating risk; Medicago’s plant-based vaccine technology to find out.
The White House Launches Supply Chain Task Force
The Biden Administration has released its 100-day supply chain assessment for semiconductor manufacturing and advanced packaging, large-capacity batteries, critical minerals and materials, and pharmaceuticals. After a year in which supply chains throughout the nation were decimated by the pandemic, the new task force intends to get the country back on track.
These measures come just in time. Semiconductor shortages have crippled the nation’s automotive manufacturers, and the new Innovation and Competition Act will strain ties between the U.S. and China. The United States needs to invest in resilient and secure supply chains, as well as help its manufacturing companies survive the pandemic.
What’s Happened Already?
Since February, the administration’s COVID-19 response team has vaccinated 137 million Americans, worked with semiconductor manufacturers, expanded rare earth element mining outside of China, and addressed supply chain cyber vulnerabilities. “Unfair trade practices by competitor nations, private- and public-sector prioritisation of low-cost labour and a focus on short-term returns over long-term investment have hollowed out the U.S. industrial base”, said the White House.
To address risks and vulnerabilities, the administration will also prioritise the following steps:
- Commit US$60mn to develop novel platform technologies to boost API production
- Develop a domestic lithium battery supply chain to combat the climate crisis
- Support manufacturers of advanced battery cells and packs with US$17bn in loans
- Invest nearly US$75bn in semiconductor manufacturing
- Give US$100mn in grants to state-led supply chain apprenticeship programmes
In addition, the White House recommended that the nation should establish a Supply Chain Resilience Programme backed by US$50bn in domestic supply chain investments.
An International Effort
Although the United States has recently doubled down on hardline stances against foreign trade competition—one need only look at its recent Senate bill—the scale of its supply chain transformation programme requires partnership. “Even as the U.S. makes investments to expand domestic production capacity for some critical products, we must work with allies to secure supplies of critical goods that we will not make in sufficient quantities at home”, the White House stated.
In the coming months, the U.S. will work with international allies such as the Quad and the G7 in order to diversify its networks, ensure human rights compliance, and source critical minerals and materials. And though the nation is aggressively investing in R&D and competitive technology, it wants to maintain its global trade ties. “U.S. investments abroad must incentivise environmentally and socially responsible production”, the administration wrote. “We must engage our partners to promote global resilience”.